Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
17 shown of 6,973 total abstracts
  1. Abstract 98762026-06-03 · 16:45 CT · S100A
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-639
    F. Andre, R. Herbst, C. Robert, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionMelanoma📄🖼️🎬
  2. Abstract 104992026-06-03 · 13:15 CT · S100A
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-221
    M. Reck, F. Andre, H. Rugo, et al. · Chinese University of Hong Kong
    Oral Abstract SessionMelanoma📄🖼️🎬
  3. Abstract 100402026-06-02 · 16:45 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    S. Antonia, A. Spira, S. Tolaney · Princess Margaret Cancer Centre
    Oral Abstract SessionMelanoma📄🖼️🎬
  4. Abstract 99102026-06-05 · 20:00 CT · S406
    KEYNOTE-880: Keytruda (pembrolizumab) 1L in metastatic melanoma
    A. Spira, C. Saura, M. Krop · Massachusetts General Hospital
    Oral Abstract SessionMelanoma📄🖼️🎬
  5. Abstract 103962026-06-02 · 21:15 CT · S406
    Long-term follow-up of Opdivo 2L for metastatic melanoma: CheckMate-327
    J. Cortes, T. Mok, M.C. Garassino, et al. · Chinese University of Hong Kong
    Oral Abstract SessionMelanoma📄🖼️🎬
  6. Abstract 104482026-06-03 · 16:45 CT · S100A
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    H. Borghaei, C. Saura · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionMelanoma📄🖼️🎬
  7. Abstract 96512026-06-03 · 14:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-630 study)
    G. Curigliano, T. Mok, H. Rugo, et al. · National Cancer Center Japan
    Oral Abstract SessionMelanoma📄🖼️🎬
  8. Abstract 99552026-06-03 · 13:00 CT · Hall B1
    CheckMate-95: Opdivo (nivolumab) maintenance in metastatic melanoma
    J. Cortes, J. Brahmer, E. Winer, et al. · University of Chicago
    Oral Abstract SessionMelanoma📄🖼️🎬
  9. Abstract 104492026-06-02 · 19:15 CT · S406
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    C. Saura, M. Reck, T. Mok · Royal Marsden Hospital
    Oral Abstract SessionMelanoma📄🖼️🎬
  10. Abstract 95702026-06-04 · 20:15 CT · S100A
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-550
    S. Tolaney, T. Mok, H. Rugo · National Cancer Center Japan
    Oral Abstract SessionMelanoma📄🖼️🎬
  11. Abstract 104112026-06-01 · 21:45 CT · E450
    CheckMate-230: Opdivo (nivolumab) neoadjuvant in metastatic melanoma
    S. Modi, S. Peters, E. Winer · Princess Margaret Cancer Centre
    Oral Abstract SessionMelanoma📄🖼️🎬
  12. Abstract 97892026-06-05 · 21:00 CT · E450
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-736 study)
    R. Herbst, C. Saura · Chinese University of Hong Kong
    Oral Abstract SessionMelanoma📄🖼️🎬
  13. Abstract 100682026-06-05 · 20:30 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-85 study)
    H. Borghaei, P. Schmid, S. Antonia · National Cancer Center Japan
    Oral Abstract SessionMelanoma📄🖼️🎬
  14. Abstract 103712026-06-03 · 19:45 CT · Hall B1
    CheckMate-881: Opdivo (nivolumab) maintenance in metastatic melanoma
    J. Brahmer, R. Herbst, P. Schmid, et al. · Cleveland Clinic
    Oral Abstract SessionMelanoma📄🖼️🎬
  15. Abstract 101852026-06-04 · 15:45 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-175 study)
    H. Borghaei, M. Reck · Royal Marsden Hospital
    Oral Abstract SessionMelanoma📄🖼️🎬
  16. Abstract 99792026-06-02 · 15:45 CT · Hall B1
    Long-term follow-up of Opdivo neoadjuvant for metastatic melanoma: CheckMate-28
    S. Antonia, H. Borghaei, S. Tolaney, et al. · National Cancer Center Japan
    Oral Abstract SessionMelanoma📄🖼️🎬
  17. Abstract 100522026-06-04 · 13:00 CT · Hall B1
    CheckMate-308: Opdivo (nivolumab) 1L in metastatic melanoma
    A. Spira, J. Cortes · Massachusetts General Hospital
    Oral Abstract SessionMelanoma📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.